Silencing SK1 sensitizes prostate tumors to docetaxel chemotherapy7, 8 and can potentially provide a new chemotherapeutic modality for patients with prostate cancer resistant to docetaxel. The gene discussed is SPHK1; the disease is prostate carcinoma.